Autres langues Celldex Therapeutics, Inc.

Actions

CLDX

US15117B2025

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 22/05/2024			Varia. 5j.	Varia. 1 janv.
38,1 ^USD	+1,14 %		-5,15 %	-3,93 %

15/05	Celldex Therapeutics annonce que le premier patient a été traité dans le cadre d'une étude de phase 2 sur les troubles cutanés	MT
15/05	Celldex Therapeutics, Inc. annonce le dosage du premier patient dans l'étude de phase 2 du barzolvolimab dans le prurigo nodulaire	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study	15/05
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis	15/05
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis	15/05
Celldex: Q1 Earnings Snapshot	06/05
Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $156,000	06/05
Celldex Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update	06/05
Sector Update: Health Care Stocks Mixed Wednesday Afternoon	17/04
Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise	17/04
Celldex Therapeutics : Corporate Presentation	17/04
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	17/04
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	17/04
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	08/03
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares	06/03
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference	06/03
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference	05/03
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares	05/03
Celldex Therapeutics Prices $400.4 Million Common Stock Offering	01/03
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock	01/03
Celldex Therapeutics Proposes $250 Million Underwritten Common Stock Offering	28/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Celldex Therapeutics, Inc.

Actions

CLDX

US15117B2025

Autres langues

Filtres